VCNX VACCINEX, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1205922 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.4%
TTM net income YoY8.0%
TTM EPS YoY79.7%
Revenue 3-yr CAGR-12.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,117.3%
Net margin-3,100.5%
FCF margin-2,696.8%
EBITDA margin-3,101.8%
Returns
ROE—
ROA-598.5%
ROIC (approx.)—
Asset turnover0.19x
Leverage & solvency
Liabilities / assets195.8%
Debt / equity—
Current ratio0.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-78.6%
Payout ratio—
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q4*2023-12-31 | 2023Q32023-09-30 | 2023Q2*2023-06-30 | 2023Q12023-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $213,000 | $52,000 | $232,000 | $104,000 | $0 | $20,000 | $0 | $550,000 |
| R&D expense | $2.13M | $3.17M | $3.86M | $3.38M | $3.36M | $4.36M | $5.05M | $3.81M |
| SG&A expense | $1.47M | $1.44M | $2.09M | $1.79M | $1.63M | $1.50M | $2.03M | $1.72M |
| Operating income | -$3.39M | -$4.55M | -$5.72M | -$5.07M | -$4.99M | -$5.83M | -$7.08M | -$4.99M |
| Interest expense | — | — | — | — | $0 | $0 | $0 | $0 |
| Pretax income | -$3.37M | -$5.73M | -$5.63M | -$3.90M | -$3.32M | -$4.91M | -$7.06M | -$4.96M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.37M | -$5.73M | -$5.63M | -$3.90M | -$3.32M | -$4.91M | -$7.06M | -$4.96M |
| EBITDA | -$3.37M | -$4.53M | -$5.70M | -$5.05M | -$4.96M | -$5.80M | -$7.05M | -$4.96M |
| EPS (basic) | — | -2.83 | -3.10 | -2.94 | — | -15.25 | -24.54 | -20.89 |
| EPS (diluted) | — | -2.83 | -3.10 | -2.94 | — | -15.25 | -24.54 | -20.89 |
| Weighted avg. shares (diluted) | — | 2.03M | 1.82M | 1.33M | — | 322,153 | 287,719 | 237,527 |
| Balance sheet | ||||||||
| Cash & equivalents | $1.11M | $2.91M | $233,000 | $2.97M | $1.53M | $127,000 | $1.91M | $3.32M |
| Receivables | $838,000 | $985,000 | $1.04M | $2.77M | $961,000 | $933,000 | $11,000 | — |
| Current assets | $2.53M | $4.76M | $2.20M | $7.15M | $3.35M | $2.21M | $2.68M | $4.42M |
| PP&E, net | $65,000 | $82,000 | $106,000 | $110,000 | $136,000 | $164,000 | $177,000 | $207,000 |
| Total assets | $2.60M | $4.85M | $2.37M | $7.37M | $3.63M | $2.56M | $3.08M | $4.89M |
| Current liabilities | $5.08M | $6.17M | $5.23M | $4.71M | $5.92M | $6.36M | $3.38M | $2.31M |
| Short-term debt | $25,000 | $44,000 | $63,000 | $76,000 | $75,000 | $75,000 | $75,000 | $75,000 |
| Long-term debt | $0 | — | — | $6,000 | $26,000 | $44,000 | $63,000 | $82,000 |
| Total debt | $25,000 | — | — | $82,000 | $101,000 | $119,000 | $138,000 | $157,000 |
| Total liabilities | $5.08M | $6.17M | $5.23M | $4.71M | $5.94M | $6.43M | $3.51M | $2.50M |
| Shareholders' equity | -$2.49M | -$1.32M | -$2.86M | $2.65M | -$2.31M | -$3.87M | -$423,000 | $2.40M |
| Net debt | -$1.08M | — | — | -$2.89M | -$1.43M | -$8,000 | -$1.77M | -$3.17M |
| Shares outstanding | 2.68M | 2.60M | — | 1.58M | 892,617 | 4.86M | 65.67M | 54.86M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.93M | -$3.21M | -$4.42M | -$4.63M | -$3.59M | -$3.10M | -$5.51M | -$5.04M |
| Capital expenditure | $0 | $8,000 | $14,000 | $0 | $0 | $18,000 | $0 | $49,000 |
| Free cash flow | -$3.93M | -$3.21M | -$4.43M | -$4.63M | -$3.59M | -$3.11M | -$5.51M | -$5.09M |
| Investing cash flow | $0 | -$8,000 | -$14,000 | $0 | $0 | -$18,000 | $0 | -$49,000 |
| Financing cash flow | $2.13M | $5.89M | $1.69M | $6.07M | $5.00M | $1.33M | $4.09M | $2.02M |
| Depreciation & amortization | $17,000 | $24,000 | $25,000 | $27,000 | $26,500 | $31,000 | $30,000 | $31,000 |
| Stock-based compensation | $57,000 | $76,000 | $112,000 | $96,000 | $104,000 | $115,000 | $126,000 | $129,000 |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.